Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

2011108 citationsJournal Articlebronze Open Access

Authors

Nathan Fowler · Cancer Research Center

Brad S. Kahl · Cancer Research Center

Peter P. Lee · Cancer Research Center

Jeffrey Matous · Cancer Research Center

Amanda F. Cashen · Cancer Research Center

Samuel A. Jacobs · Cancer Research Center

Jeffrey Letzer ·

Abstract

The combination of bortezomib, bendamustine, and rituximab is highly active in patients with follicular lymphoma who have received previous treatment.

Topics & Keywords

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Viral-associated cancers and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 29, Issue 25, pp. 3389-3395

DOI: 10.1200/jco.2010.32.1844

Field-Weighted Citation Impact: 11.47